Sands Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Sands Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-856,472	Closed	-$479M	–	84
2020 Q3	$479M	Buy	856,472 +17,057	+2%	+$10.3M	1.04%	34
2020 Q2	$524M	Buy	839,415 +695	+0.1%	+$394K	1.27%	28
2020 Q1	$410M	Sell	838,720 -13,991	-2%	-$5.77M	1.37%	26
2019 Q4	$320M	Sell	852,711 -36,777	-4%	-$12.4M	0.93%	31
2019 Q3	$247M	Sell	889,488 -81,678	-8%	-$24.2M	0.79%	36
2019 Q2	$304M	Sell	971,166 -1,016,547	-51%	-$338M	0.9%	31
2019 Q1	$816M	Sell	1,987,713 -93,116	-4%	-$38.3M	2.52%	14
2018 Q4	$777M	Sell	2,080,829 -96,564	-4%	-$35.3M	2.77%	13
2018 Q3	$880M	Sell	2,177,393 -128,418	-6%	-$48.9M	2.49%	16
2018 Q2	$795M	Sell	2,305,811 -98,276	-4%	-$30.7M	2.28%	16
2018 Q1	$828M	Sell	2,404,087 -152,525	-6%	-$53.1M	2.45%	15
2017 Q4	$961M	Sell	2,556,612 -83,298	-3%	-$33.7M	2.91%	13
2017 Q3	$1.18B	Sell	2,639,910 -154,049	-6%	-$73.3M	3.54%	10
2017 Q2	$1.37B	Sell	2,793,959 -139,485	-5%	-$61M	4.13%	6
2017 Q1	$1.14B	Buy	2,933,444 +630,642	+27%	+$234M	3.57%	10
2016 Q4	$845M	Sell	2,302,802 -194,576	-8%	-$74M	2.95%	11
2016 Q3	$1B	Sell	2,497,378 -162,363	-6%	-$65.1M	2.96%	13
2016 Q2	$929M	Sell	2,659,741 -728,180	-21%	-$280M	2.87%	13
2016 Q1	$1.22B	Sell	3,387,921 -310,632	-8%	-$128M	3.61%	9
2015 Q4	$2.01B	Sell	3,698,553 -439,631	-11%	-$238M	5.17%	3
2015 Q3	$1.92B	Sell	4,138,184 -80,784	-2%	-$43.4M	5.37%	4
2015 Q2	$2.15B	Sell	4,218,968 -791,193	-16%	-$386M	5.29%	3
2015 Q1	$2.26B	Buy	5,010,161 +23,984	+0.5%	+$10.2M	5.38%	3
2014 Q4	$2.05B	Buy	4,986,177 +18,711	+0.4%	+$7.36M	4.87%	5
2014 Q3	$1.79B	Buy	4,967,466 +60,104	+1%	+$20.1M	4.45%	6
2014 Q2	$1.39B	Buy	4,907,362 +895,300	+22%	+$265M	3.49%	12
2014 Q1	$1.2B	Buy	4,012,062 +279,382	+7%	+$86.1M	3.14%	14
2013 Q4	$1.03B	Sell	3,732,680 -44,677	-1%	-$12.8M	2.69%	17
2013 Q3	$1.18B	Buy	3,777,357 +638,564	+20%	+$168M	3.3%	12
2013 Q2	$706M	Buy	+3,138,793	New	+$731M	2.38%	22

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sands Capital Management's REGN Position: Q4 2020 in Review

Sands Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 856,472 shares — an estimated $479M sold.

Sands Capital Management first reported a position in REGN in Q2 2013 and held it in 30 quarters. The position peaked at $2.26B in Q1 2015. 903 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

Sands Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Sands Capital Management sold 856,472 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $479M.
Sands Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 30 quarters.
Sands Capital Management's Regeneron Pharmaceuticals position peaked at $2.26B in Q1 2015.
903 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Sands Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.